Rational Antibody-based HIV-1 Vaccine Design: Current Approaches and Future Directions

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2010 Mar 20

PMID 20299194

Citations 125

Authors

Laura M Walker

Dennis R Burton

Affiliations

Soon will be listed here.

Abstract

Many antiviral vaccines elicit neutralizing antibodies as a correlate of protection. For HIV, given the huge variability of the virus, it is widely believed that the induction of a broadly neutralizing antibody (bNAb) response will be crucial in a successful vaccine against the virus. Unfortunately, despite many efforts, the development of an immunogen that elicits bNAbs remains elusive. However, recent structural studies of HIV-1 Env proteins, generation of novel bNAbs, maturation of technologies for the isolation of further antibodies, insights into the requirements for antibody-mediated protection, and novel vaccination approaches are providing grounds for renewed optimism.

Citing Articles

Rational design of next-generation filovirus vaccines with glycoprotein stabilization, nanoparticle display, and glycan modification.

Lee Y, Zhang Y, Newby M, Ward G, Gomes K, Auclair S bioRxiv. 2025; .

PMID: 40060701 PMC: 11888476. DOI: 10.1101/2025.03.02.641072.

The CH1 domain influences the expression and antigen sensing of the HIV-specific CH31 IgM-BCR and IgG-BCR.

Ortiz Y, Anasti K, Kane A, Cronin K, Alam S, Reth M Proc Natl Acad Sci U S A. 2024; 121(31):e2404728121.

PMID: 39042672 PMC: 11295018. DOI: 10.1073/pnas.2404728121.

Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand.

Temchura V, Wagner J, Damm D Pharmaceutics. 2024; 16(1).

PMID: 38258035 PMC: 10818441. DOI: 10.3390/pharmaceutics16010024.

Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimmers as HIV-1 vaccine candidates.

Zhang Y, Paynter J, Antanasijevic A, Allen J, Eldad M, Lee Y Nat Commun. 2023; 14(1):1985.

PMID: 37031217 PMC: 10082823. DOI: 10.1038/s41467-023-37742-z.

Structural Elucidation of a Protective B Cell Epitope on Outer Surface Protein C (OspC) of the Lyme Disease Spirochete, Borreliella burgdorferi.

Rudolph M, Davis S, Haque H, Weis D, Vance D, Piazza C mBio. 2023; 14(2):e0298122.

PMID: 36976016 PMC: 10128040. DOI: 10.1128/mbio.02981-22.

References

Parren P, Marx P, Hessell A, Luckay A, Harouse J, Cheng-Mayer C . Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001; 75(17):8340-7. PMC: 115078. DOI: 10.1128/jvi.75.17.8340-8347.2001. View

Gupta K, Hudgens M, Corey L, McElrath M, Weinhold K, Montefiori D . Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr. 2002; 29(3):254-61. DOI: 10.1097/00126334-200203010-00005. View

Marsac D, Loirat D, Petit C, Schwartz O, Michel M . Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1.... J Virol. 2002; 76(15):7544-53. PMC: 136357. DOI: 10.1128/jvi.76.15.7544-7553.2002. View

Lewis A, Chen R, Montefiori D, Johnson P, Clark K . Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol. 2002; 76(17):8769-75. PMC: 136414. DOI: 10.1128/jvi.76.17.8769-8775.2002. View

Burton D . Antibodies, viruses and vaccines. Nat Rev Immunol. 2002; 2(9):706-13. DOI: 10.1038/nri891. View

Joyce J, Hurni W, Bogusky M, Garsky V, Liang X, Citron M . Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem. 2002; 277(48):45811-20. DOI: 10.1074/jbc.M205862200. View

Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S . Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol. 2002; 77(1):353-65. PMC: 140593. DOI: 10.1128/jvi.77.1.353-365.2003. View

Pantophlet R, Saphire E, Poignard P, Parren P, Wilson I, Burton D . Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol. 2002; 77(1):642-58. PMC: 140633. DOI: 10.1128/jvi.77.1.642-658.2003. View

McGaughey G, Citron M, Danzeisen R, Freidinger R, Garsky V, Hurni W . HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry. 2003; 42(11):3214-23. DOI: 10.1021/bi026952u. View

10.

Pantophlet R, Wilson I, Burton D . Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol. 2003; 77(10):5889-901. PMC: 154011. DOI: 10.1128/jvi.77.10.5889-5901.2003. View

11.

Kim J, Pitisuttithum P, Kamboonruang C, Chuenchitra T, Mascola J, Frankel S . Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1. AIDS Res Hum Retroviruses. 2003; 19(9):807-16. DOI: 10.1089/088922203769232601. View

12.

Ofek G, Tang M, Sambor A, Katinger H, Mascola J, Wyatt R . Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004; 78(19):10724-37. PMC: 516390. DOI: 10.1128/JVI.78.19.10724-10737.2004. View

13.

Hu S, Abrams K, Barber G, Moran P, Zarling J, Langlois A . Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992; 255(5043):456-9. DOI: 10.1126/science.1531159. View

14.

Baldridge J, Buchmeier M . Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J Virol. 1992; 66(7):4252-7. PMC: 241229. DOI: 10.1128/JVI.66.7.4252-4257.1992. View

15.

Moore J, Cao Y, Qing L, Sattentau Q, Pyati J, Koduri R . Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 1995; 69(1):101-9. PMC: 188553. DOI: 10.1128/JVI.69.1.101-109.1995. View

16.

Pialoux G, Excler J, Riviere Y, Feuillie V, Coulaud P, Gluckman J . A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses. 1995; 11(3):373-81. DOI: 10.1089/aid.1995.11.373. View

17.

Mascola J, Snyder S, Weislow O, Belay S, Belshe R, Schwartz D . Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine.... J Infect Dis. 1996; 173(2):340-8. DOI: 10.1093/infdis/173.2.340. View

18.

Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W . Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999; 5(2):204-10. DOI: 10.1038/5568. View

19.

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

20.

Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J . Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology. 2004; 331(1):33-46. DOI: 10.1016/j.virol.2004.09.022. View